The all-in-one platform to find and track your investments
Discover the features
Statistics
Market Cap
120 billion
PE Ratio
14.88 x
Beta (volatility)
0.42
Earnings Per Share
5.29
About
ISIN : FR0000120578
It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Heal
Price over 10 years
Performance Comparison
| Sanofi SA | |
|---|---|
| 1 year return |
-1 %
|
| 5 years return |
+14 %
|
Valuation (BETA)
For this company, we show you a quick help in graphical form that tells you if the stock looks overvalued, undervalued or fairly priced, and by how much. Stop paying too much for your shares.
Unlock valuation chart for this company
Dividend History
Uninter. Dividend
30 years +
Frequency
1x / year
Dividends in 2021
May
Dividends in 2020
May
May
Dividends in 2020
May
Forward Annual Amount
€3.33
Ex-dividend
5/6/2022
Financials
Year-over-Year growth
Profitability
Health
Valuation
| Price to Book | Payout ratio | PE Ratio | PEG Ratio |
|---|---|---|---|
| 1.38 | 63 % | 14.88 x | 1.57 |
| Price to Sales | Price / FCF | Enterprise Value Revenue |
|---|---|---|
| 3.07 | 11.6 | 2.66 |
News
Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate
9/30/2022
Sarepta Therapeutics SRPT submitted a biologics license application (BLA) to the FDA seeking accelerated approval for its gene therapy candidate, SRP-9001, to treat ambulant patients with Duchenne muscular dystrophy (DMD).
The therapy is being develop
Is Novartis (NVS) a Great Value Stock Right Now?
9/29/2022
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks.
Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momen
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
9/28/2022
Sanofi - Aventis Groupe
Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two piv
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
9/28/2022
Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trialsAbout 75,000 a
Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
9/28/2022
Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials
About 75,000 adults in the U.S.
living with prurigo nodularis are most in need of new treatment options
Approval r
UPDATE 1-French drugmaker Sanofi expects positive boost from currency markets in Q3
9/28/2022
(Adds detail and background)
PARIS, Sept 28 (Reuters) - French drugmaker Sanofi said it expected a positive boost to its third-quarter business results from movements on the currency markets, helped by the strength of the U.S.
dollar since Sanofi doe
French drugmaker Sanofi expects positive boost from currency markets in Q3
9/28/2022
PARIS (Reuters) -French drugmaker Sanofi said it expected a positive boost to its third-quarter business results from movements on the currency markets, helped by the strength of the U.S.
dollar since Sanofi does much of its business in the United Sta
Press Release: Availability of the Q3 2022 Memorandum for modelling purposes
9/28/2022
Availability of the Q3 2022 Memorandum for modelling purposes
Paris, France – September 28, 2022 - Sanofi announced today that its Q3 2022 Memorandum for modelling purposes is available on the "Investors" page of the company's website:
https://www.s
Press Release: Availability of the Q3 2022 Memorandum for modelling purposes
9/28/2022
Sanofi - Aventis Groupe
Availability of the Q3 2022 Memorandum for modelling purposes
Paris, France – September 28, 2022 - Sanofi announced today that its Q3 2022 Memorandum for modelling purposes is available on the "Investors" page of the company'
Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors
9/22/2022
Eli Lilly LLY announced that the FDA granted accelerated approval to Retevmo (selpercatinib) in adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion, regardless of tumor type.
The drug
Novartis (NVS) to Appeal to Supreme Court for Gilenya Patent
9/22/2022
Novartis NVS plans to file a petition in the U.S.
Supreme Court to uphold the validity of the Gilenya (fingolimod) dosing regimen patent.
This comes after the U.S.
Court of Appeals for the Federal Circuit (“CAFC”) denied its petition to rehear the ne
AstraZeneca (AZN) Gets EU Nod for Evusheld to Treat COVID
9/21/2022
AstraZeneca AZN announced that the European Commission (EC) granted marketing authorization to its long-acting cocktail antibody therapy, Evusheld, for the treatment of COVID-19.
Evusheld, which is a combination of tixagevimab and cilgavimab, has bee
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy
|
Terms and Conditions
© Copyright 2020-2022 Epsylia OÜ - All rights reserved